Compare YAAS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YAAS | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 10.9M |
| IPO Year | 2023 | 2023 |
| Metric | YAAS | CMMB |
|---|---|---|
| Price | $0.70 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 9.1K | ★ 59.0K |
| Earning Date | 08-27-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $28.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.92 |
| 52 Week High | $4.98 | $2.99 |
| Indicator | YAAS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 43.53 |
| Support Level | $0.56 | $0.99 |
| Resistance Level | $1.05 | $1.91 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 20.74 |
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.